In-Vitro Colorectal Cancer Screening Tests Market Size, Share, Growth Analysis, By Test Type (Fecal Occult Blood Tests, Biomarker Tests), By End User (Hospitals, Clinics), By Region - Industry Forecast 2025-2032

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 23.79 Billion in 2023 and is poised to grow from USD 26.43 Billion in 2024 to USD 71.88 Billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

Adenomas, polyps, and colorectal cancer symptoms can all be found with in-vitro tests for colorectal cancer screening. A disorder known as colorectal cancer is characterised by the abnormal proliferation of cells in the colon, rectum, and large intestine. Some of the frequently used screening tests include the guaiac FOB stool test, lateral flow immuno, transferrin assays, methylated gene, biomarker, and faecal occult blood (FOB) test. In-vitro colorectal cancer screening procedures employ cameras that take pictures of the digestive system and send them to a recorder fastened to the patient's waist. They are seldom intrusive and can help with early cancer detection. In-vitro colorectal cancer screening procedures are therefore frequently carried out in clinics, hospitals, and diagnostics laboratories. The main factors anticipated to propel the in-vitro colorectal cancer screening tests market over the projected period are the rising occurrences of colon and rectal cancer and the release of innovative screening tests utilising genetic testing. The market for in-vitro colorectal cancer screening tests is anticipated to grow as a result of the introduction of government regulations aimed at requiring the use of cancer screening tests, rising demand for novel, minimally invasive tests that screen for colorectal cancer using DNA and genetic biomarkers, and the rising prevalence of colorectal cancer.

US In-Vitro Colorectal Cancer Screening Tests Market  is poised to grow at a sustainable CAGR for the next forecast year.